Neogen Chemicals Limited

🔴 Bear CaseWhat could go wrong?

1. The debt load needs earnings to hold up
   Debt is 10.8x EBITDA. At that level a downturn in earnings turns a manageable balance sheet into a refinancing problem, and lenders get paid before shareholders.
2. Sales are being booked faster than collected
   Receivables are up 114% against revenue up 28%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
3. The price already assumes success
   The stock trades 69% above its own median multiple. At this level the business has to deliver just to stand still, and a stumble is repriced twice — lower earnings on a lower multiple.
4. Returns on shareholder capital are falling
   ROE has dropped from 10.4% to 3.5%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
5. Size brings its own risk
   Small Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.